[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07635147":3,"trial-entities:NCT07635147":127,"trial-summary:NCT07635147":131},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":23,"study_type":28,"primary_purpose":29,"phases":30,"enrollment_info":32,"interventions":35,"primary_outcomes":42,"secondary_outcomes":54,"sex":65,"minimum_age":66,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":67,"std_ages":76,"locations":79,"central_contacts":117,"overall_officials":123,"references":125,"see_also_links":126},"NCT07635147","25-07029092","Decision Support Tool for Patients With Advanced Breast Cancer","Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)","RECRUITING","2028-02","2026-07","2026-07-17","2026-06","Weill Medical College of Cornell University","OTHER",false,"The goal of this pilot study is to understand and improve the shared decision-making process between people with advanced breast cancer and their providers regarding their care and treatment. As part of this study, the researchers will evaluate a decision support tool called COAST that was designed to support patients and providers in having meaningful conversations. The main questions it aims to answer are:\n\n1. Can the COAST tool improve the quality of communication between patients and their oncology providers?\n2. Is the COAST tool acceptable, appropriate, and easy to use at NYP-Weill Cornell Medicine, NYP-Brooklyn Methodist Hospital and NYP-Queens?\n\nParticipants will be asked to fill out two surveys: one before they use the COAST tool and another about 2 - 4 weeks later. Some patients will also be invited for an interview.",null,[19,20,21,22],"Breast Cancer Metastatic","Advanced Breast Cancer","Stage 4 Breast Cancer","Stage IV (Metastatic) Breast Cancer",[24,25,26,27],"Decision support tool","advanced breast cancer","communication","Treatment preferences","INTERVENTIONAL","SUPPORTIVE_CARE",[31],"NA",{"count":33,"type":34},100,"ESTIMATED",[36],{"type":37,"name":38,"description":39,"armGroupLabels":40},"BEHAVIORAL","Decision Support Tool","The COAST decision support tool will be available in two formats: a booklet and a website. It will provide information about advanced breast cancer and the available treatment options. Participants will be guided through questions designed to clarify their goals and preferences, identify support needs, and concerns they may have.",[41],"COAST intervention",[43,47,50],{"measure":44,"description":45,"timeFrame":46},"Patient-reported acceptability of the COAST decision support tool","The proportion of patients who agree with the acceptability of the COAST decision support tool is measured by the Acceptability of Intervention Measure (AIM). This tool consists of four items designed to monitor and evaluate the success of implementation efforts. Respondents can rate each item on a scale from 1 (completely disagree) to 5 (completely agree). Higher scores reflect greater agreement with the acceptability of the intervention.\n\nPatients with a score of 4 or higher will be included in the numerator, while all patients who complete the measure will be included in the denominator. We will define COAST as \"acceptable\" if this proportion is greater than 70%.","2-4 weeks after exposure to COAST",{"measure":48,"description":49,"timeFrame":46},"Patient-reported appropriateness of the COAST decision support tool","The proportion of patients who agree with the appropriateness of the COAST decision support tool is measured using the Intervention Appropriateness Measure (IAM). This tool consists of four items designed to evaluate the suitability and relevance of an intervention. Respondents can rate each item on a scale from 1 (completely disagree) to 5 (completely agree).\n\nHigher scores reflect greater agreement with the appropriateness of the intervention.\n\nPatients with a score of 4 or higher will be included in the numerator, while all patients who complete the measure will be included in the denominator. We will define COAST as \"appropriate\" if this proportion is greater than 70%.",{"measure":51,"description":52,"timeFrame":53},"Provider-reported feasibility of the COAST decision support tool","The proportion of healthcare providers who care for adult patients with metastatic breast cancer (MBC) and agree on the feasibility of the COAST decision support tool is measured using the Feasibility of Intervention Measure (FIM). This tool consists of four items designed to measure the feasibility or extent to which an intervention can be successfully used or carried out within a given setting. Respondents can rate each item on a scale from 1 (completely disagree) to 5 (completely agree). Higher scores reflect greater agreement with the feasibility of implementing the COAST tool.\n\nProviders with a score of 4 or higher will be included in the numerator, while all providers who complete the measure will be included in the denominator. We will define COAST as \"feasible\" if this proportion is 70% or greater.","At the conclusion of participant enrollment, approximately 1 month after the last patient is enrolled.",[55,59,62],{"measure":56,"description":57,"timeFrame":58},"Change in Baseline Decisional Conflict Scale Score","Mean change from baseline in patient decisional conflict will be assessed via Decisional Conflict Scale (DCS), which includes 5 subscales (uncertainty, informed, values clarity, support, effective decision). Each item is rated on a scale of 0 (strongly agree) to 4 (strongly disagree). Scores range from 0-100 with higher scores indicating more decisional conflict.","Baseline and follow-up (2-4 weeks after exposure to COAST)",{"measure":60,"description":61,"timeFrame":58},"Change in patient-centered communication","Mean change from baseline in patient-centered communication score will be assessed via Patient-Centered Communication (PCC) in cancer care. The purpose of the measure is to assess PCC in six core domains: 1) exchanging information, 2) making decisions, 3) fostering healing relationships, 4) enabling patient self-management, 5) managing uncertainty, and 6) responding to emotions. Respondents can rate each item on a scale, where higher scores indicate better patient-centered communication and greater perceived support from the healthcare team.",{"measure":63,"description":64,"timeFrame":58},"Change in decisional self-efficacy score","Mean Change from Baseline in patient self-efficacy for making decisions will be assessed via the Decisional Self-Efficacy Scale. The Scale measures self-confidence or belief in one's abilities in decision making, including shared decision-making. Respondents can rate each item on a scale from 0 (not at all confident) to 4 (very confident). A score of 0 means \"extremely low self-efficacy\" and a score of 100 means \"extremely high self-efficacy\".","ALL","18 Years",{"inclusion":68,"exclusion":72,"raw_text":75},[69,70,71],"Male or female 18 years and older","Diagnosis of Stage IV breast cancer","English, Spanish or Mandarin speaking",[73,74],"Early breast cancer","Individuals speaking languages other than English, Spanish, or Mandarin as their primary language","Inclusion Criteria:\n\n* Male or female 18 years and older\n* Diagnosis of Stage IV breast cancer\n* English, Spanish or Mandarin speaking\n\nExclusion Criteria:\n\n* Early breast cancer\n* Individuals speaking languages other than English, Spanish, or Mandarin as their primary language",[77,78],"ADULT","OLDER_ADULT",[80,98,109],{"facility":81,"status":8,"city":82,"state":83,"zip":84,"country":85,"contacts":86,"geoPoint":95},"NewYork-Presbyterian Brooklyn Methodist Hospital","Brooklyn","New York","11215","United States",[87,92],{"name":88,"role":89,"phone":90,"email":91},"Zori K Hamilton, MA","CONTACT","6469623694","zkh4001@med.cornell.edu",{"name":93,"role":94},"Evelyn Taiwo, MD","PRINCIPAL_INVESTIGATOR",{"lat":96,"lon":97},40.6501,-73.94958,{"facility":99,"status":8,"city":83,"state":83,"zip":100,"country":85,"contacts":101,"geoPoint":106},"NewYork-Presbyterian David H. Koch Center","10065",[102,104],{"name":88,"role":89,"phone":103,"email":91},"646-962-3694",{"name":105,"role":94},"Shoshana Rosenberg, ScD, MPH",{"lat":107,"lon":108},40.71427,-74.00597,{"facility":110,"status":8,"city":83,"state":83,"zip":111,"country":85,"contacts":112,"geoPoint":116},"NewYork-Presbyterian Medical Group Queens","11355",[113,114],{"name":88,"role":89,"phone":103,"email":91},{"name":115,"role":94},"Pooja Murthy, MD",{"lat":107,"lon":108},[118,119],{"name":88,"role":89,"phone":103,"email":91},{"name":120,"role":89,"phone":121,"email":122},"Darima Dorzhieva","646-962-8666","dad4011@med.cornell.edu",[124],{"name":105,"affiliation":13,"role":94},[],[],{"nct_id":4,"conditions":128,"biomarkers":130},[129],"Breast Carcinoma",[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]